Medical Device Clinical Trials on ClinicalTrials.gov by the Numbers (2026)

A deep quantitative teardown of the ClinicalTrials.gov database for medical devices. Analysis of phase NA dominance, results-reporting compliance, sponsor classes, and decadal growth trends.

When clinical-affairs leaders, R&D strategists, and MedTech investors plan clinical investigations, they often treat ClinicalTrials.gov as a simple administrative checkbox. They register their trials to satisfy regulatory mandates, publish results to avoid compliance penalties, and search the registry for competitor names. But when viewed as a complete, unified database, ClinicalTrials.gov offers a massive repository of market-intelligence and clinical-strategy data. By analyzing the medical device trial cohort quantitatively, we can map the true shape of clinical research in the MedTech industry: how device trials differ from drug trials, which clinical specialties dominate clinical research, who sponsors the most trials, and how many studies actually comply with results-reporting requirements.

This article delivers a complete quantitative teardown of medical device clinical trials registered on ClinicalTrials.gov. Based on our analysis of the primary registry database, we dissect the macro metrics of device studies, examine the dominance of academic versus industry sponsors, evaluate the "Phase NA" reality of device trial design, analyze growth trends over the last decade, and audit the results-reporting compliance gap.

Scenario Question: We are planning a medical device clinical investigation and want to benchmark against the field: how many device trials are actually on ClinicalTrials.gov, who runs them, what they study, and how phase works for devices?

Direct Answer: As of July 2026, ClinicalTrials.gov holds 593,334 registered studies, of which 62,770 are interventional studies with at least one device intervention (our analysis of the ClinicalTrials.gov data download returns 62,747, within 0.04 percent of the official count). Only 11,329 of those device studies (18 percent) have posted results. Device trials enroll an estimated 36.8 million participants cumulatively, 84.5 percent carry no drug-style phase (NA), and the sponsor base is still majority academic (OTHER sponsors 50,829 versus INDUSTRY 20,650 across all device study types), even as industry funding and cardiology or neurology conditions dominate the top of the condition ranking.

1. How Many Medical Device Trials Are Registered on ClinicalTrials.gov in 2026?

To evaluate the clinical landscape, we must first isolate medical device studies from the broader ClinicalTrials.gov database, which is dominated by pharmaceutical, biological, and behavioral interventions. As of July 10, 2026, the registry contains a total of 593,334 registered studies across all intervention types.

By filtering this population for interventional studies where at least one of the intervention arms utilizes a medical device, we identify a cohort of 62,770 device-interventional studies (our analysis of the ClinicalTrials.gov data download returns 62,747 records, representing a tiny variance of 0.04% due to weekly update propagation). This device cohort represents 10.58% of the entire ClinicalTrials.gov database.

Medical device trials represent a major patient population. Across all 62,747 device-interventional studies in our analysis of the ClinicalTrials.gov database, the cumulative number of planned or actual enrolled participants stands at 36,818,325. This represents an average enrollment size of 587 participants per study, though this figure is heavily skewed by a small number of large, observational registry-style studies and post-market screening trials. The median enrollment size for device-interventional trials is much lower, reflecting the targeted nature of device investigations compared to massive multi-center pharmaceutical trials.

Table 1: Medical Device Cohort vs. Broad ClinicalTrials.gov Database (2026)

Metric	Complete Registry	Device-Interventional Cohort	Device Share (%)
Total Registered Studies	593,334	62,770	10.58%
Interventional Studies	452,754	62,770	13.86%
Studies with Results Posted	79,112	11,329	14.32%
Results-Posting Rate (within cohort)	13.34%	18.04%	—
Cumulative Enrolled Participants	Not published	36,818,325	—

Data source: ClinicalTrials.gov NLM Trends and Charts (as of July 10, 2026) for registry totals, and analysis of the ClinicalTrials.gov data download for device-cohort enrollment.

2. Who Sponsors Device Trials: Industry, Academia, or Government?

A common misconception is that the medical device trial landscape is entirely driven by multinational MedTech corporations. In reality, academic medical centers, university hospitals, and independent research organizations conduct the vast majority of registered device trials.

ClinicalTrials.gov classifies sponsors into several categories, with the two primary classes being Industry (for-profit medical device, pharmaceutical, and biotechnology companies) and Other (academic medical centers, universities, non-profit foundations, and healthcare systems). Other categories include Federal agencies, the National Institutes of Health (NIH), and network trial groups.

Across all registered device studies (including both interventional and observational protocols), the distribution of sponsor classes shows a massive academic footprint:

Other (Academic/Non-Profit): 50,829 studies (68.04% of all device registrations)
Industry (MedTech/Pharma): 20,650 studies (27.65% of all device registrations)
Other Government (State/Local): 1,793 studies (2.40% of all device registrations)
Federal Agencies (US Government): 600 studies (0.80% of all device registrations)
Collaborative Networks: 370 studies (0.50% of all device registrations)
National Institutes of Health (NIH): 281 studies (0.38% of all device registrations)

While academic sponsors run the highest volume of trials, they are typically smaller, single-center studies focused on investigator-initiated questions, off-label indications, or comparative-effectiveness research. Industry-sponsored trials, by contrast, are typically larger, multi-center, and designed to support regulatory submissions such as FDA 510(k) clearances or PMA approvals, which must adhere to strict Good Clinical Practice (GCP) guidelines.

Top Sponsors of Medical Device Studies

When we rank individual sponsors by study volume, academic institutions lead in total count, but multinational MedTech majors dominate the industry segment:

Cairo University (Academic): 899 studies (Focusing heavily on obstetrics, gynecology, and surgical device interventions)
Assiut University (Academic): 611 studies
Boston Scientific Corporation (Industry): 474 studies (Leading all commercial sponsors globally)
Abbott Medical Devices (Industry): 452 studies (Spanning cardiovascular, neuromodulation, and diabetes care divisions)
Medtronic (Industry): 428 studies (Excluding subsidiary registrations that run under independent corporate entities)

For commercial teams, understanding this sponsor split is critical. When planning clinical-site selection, academic centers represent the primary engine of patient enrollment and clinical expertise, but they often operate under different institutional review board (IRB) timelines and clinical-trial agreement (CTA) structures than dedicated contract research organizations (CROs).

3. Why Do 84.5% of Device Trials Have No Phase, and What Does That Mean for Device Trial Design?

In drug development, the clinical pathway is defined by clear, sequential phases: Phase 1 (safety and tolerability), Phase 2 (dosing and proof of concept), Phase 3 (pivotal efficacy and safety), and Phase 4 (post-market surveillance). This phase-based paradigm is deeply hardcoded into clinical vocabulary and regulatory frameworks.

For medical devices, however, this drug-centric framework is irrelevant. Medical devices are mechanical, electrical, or software systems. Their safety and performance profiles depend on user-interface design, surgical technique, and tissue interaction rather than systemic pharmacokinetics. Consequently, the vast majority of device studies skip drug-style phases entirely.

Our database analysis reveals that 84.50% (53,020 of 62,747) of device-interventional studies designate their phase as "Not Applicable" (Phase NA).

Table 2: Phase Distribution of Device-Interventional Studies

Phase Designation	Registered Studies	Share of Device Cohort (%)	Regulatory Equivalency
Phase NA	53,020	84.50%	Feasibility, Pivotal, or Post-Market trials
Phase 4	3,923	6.25%	Post-market clinical follow-up (PMCF)
Phase 2	2,217	3.53%	Often misapplied pilot/feasibility studies
Phase 1	1,844	2.94%	Early first-in-human feasibility studies
Phase 3	1,304	2.08%	Misapplied pivotal comparative trials
Early Phase 1	439	0.70%	Preliminary safety assessments

Data source: Analysis of 62,747 device-interventional records in the ClinicalTrials.gov database.

The remaining 15.5% of trials that report a drug-style phase represent a mix of:

Combination Products: Drug-delivery systems or drug-eluting devices (e.g., drug-eluting stents, transdermal patches) that undergo review through the FDA’s Center for Drug Evaluation and Research (CDER) and require traditional phase structures.
Sponsor Misclassification: Academic sponsors or researchers who are accustomed to drug trials and incorrectly select "Phase 2" or "Phase 3" for pure medical device studies.

Designing Device Trials Outside the Phase Paradigm

Rather than relying on phases, device sponsors construct their clinical strategies around three distinct study types defined by the product lifecycle:

Feasibility / Pilot Studies: Small, early-stage trials (typically 10 to 30 patients) designed to evaluate the safety, design stability, and initial performance of a new device in humans. These trials help refine the device design and the surgical protocol before initiating larger trials.
Pivotal / Confirmative Studies: Larger, statistically powered trials designed to gather definitive evidence of safety and effectiveness. These trials support regulatory submissions, such as FDA IDE pathways or EU MDR clinical investigations.
Post-Market Studies: Trials conducted after commercialization, such as Post-Market Clinical Follow-up (PMCF) studies under the EU MDR, to monitor long-term safety, detect rare adverse events, and verify performance in real-world use.

When writing a statistical analysis plan (SAP), recognizing this phase NA reality is essential. Endpoint definitions, sample size calculations, and missing-data handling must align with the specific trial design (feasibility vs. pivotal) rather than forcing drug-phase conventions onto a device.

4. What Conditions Do Device Trials Target, and Which Areas Have the Most Activity?

Medical device research is highly concentrated in therapeutic areas that rely on implantable hardware, active electrical stimulation, or specialized surgical tools.

To identify where device research is focused, we analyzed the frequency of condition terms listed in the registry for device-interventional studies. The top five target conditions are:

Stroke: 1,627 studies (Reflecting massive investment in thrombectomy catheters, neurovascular stents, and neurorehabilitation systems)
Coronary Artery Disease: 1,022 studies (Driven by drug-eluting stents, balloon angioplasty, and intravascular imaging catheters)
Heart Failure: 900 studies (Covering cardiac resynchronization therapy devices, left ventricular assist devices, and pulmonary artery pressure monitors)
Atrial Fibrillation: 701 studies (Spanning ablation catheters, mapping systems, and left atrial appendage occlusion devices)
Breast Cancer: 691 studies (Focusing on surgical localization markers, reconstruction matrices, tissue expanders, and radiotherapy positioning systems)

Figure 1: Top Therapeutic Focus Areas in Device-Interventional Studies

Cardiovascular (CAD, Heart Failure, Atrial Fibrillation)   ██████████████████████████████ 2,623 Studies
Neurology & Stroke                                         ██████████████████ 1,627 Studies
Oncology (Breast Cancer, etc.)                             ████████ 691 Studies

This distribution highlights the commercial reality of the MedTech industry. Cardiovascular and neurological conditions dominate clinical research because they command high reimbursement rates and require robust clinical evidence to secure regulatory approvals.

For startups and investors, this mapping also reveals clinical "white spaces." While cardiology is highly saturated with clinical trials, other therapeutic areas like pediatrics, wound care, and physical medicine offer significant opportunities for clinical differentiation.

5. How Has the Device Trial Landscape Grown From 2014 to 2025?

The volume of medical device clinical trials has grown steadily over the last decade. This growth is driven by increasing regulatory demands for clinical evidence, particularly the implementation of the European Union Medical Devices Regulation (EU MDR 2017/745), which raised the clinical data requirements for CE marking.

To track this growth, we analyzed the number of device-interventional studies starting each calendar year from 2014 through 2025.

Table 3: Device-Interventional Study Start Year Trend (2014–2025)

Start Year	Registered Device-Interventional Studies	Year-over-Year Growth (%)	Cumulative Device Studies
2014	2,756	—	2,756
2015	2,904	5.37%	5,660
2016	3,114	7.23%	8,774
2017	3,354	7.71%	12,128
2018	3,694	10.14%	15,822
2019	3,904	5.68%	19,726
2020	3,745	-4.07%	23,471
2021	4,204	12.26%	27,675
2022	4,394	4.52%	32,069
2023	4,504	2.50%	36,573
2024	4,604	2.22%	41,177
2025	4,637	0.72%	45,814

Data source: Analysis of ClinicalTrials.gov records by trial start date.

Several trends emerge from this timeline:

The COVID-19 Dip (2020): In 2020, new trial starts declined by 4.07%. This was driven by widespread trial suspensions, site closures, and the redirection of hospital resources to pandemic response.
The Post-Pandemic Rebound (2021): The industry recovered quickly, with a 12.26% surge in new study starts in 2021 as delayed clinical trials were initiated and decentralized trial methodologies were adopted.
Regulatory Headwinds: The steady rise in trial starts from 2017 to 2025 matches the transition timeline of the EU MDR. Under the MDR, manufacturers of legacy CE-marked devices were forced to generate new clinical data to maintain market access, leading to a substantial increase in PMCF and post-market clinical investigations.

6. Why Do Only 18% of Device Trials Post Results, and What Are the FDAAA 801 Reporting Consequences?

Under Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA 801), sponsors of "applicable clinical trials" are legally required to register and submit summary results to ClinicalTrials.gov. The results must generally be submitted no later than one year after the primary completion date of the trial.

Despite this legal mandate, results-reporting compliance remains a major challenge in the medical device industry. Our analysis of the device-interventional cohort reveals a significant compliance gap:

Only 17.98% (11,323 of 62,747) of device-interventional studies have summary results posted on ClinicalTrials.gov.

While a portion of the remaining 82.02% consists of active, ongoing trials that have not yet reached their primary completion dates, thousands of completed studies have failed to submit results within the mandated timeline.

Why the Compliance Gap Persists

Several factors contribute to the low rate of results posting for medical devices:

Academic Under-reporting: As noted in Section 2, academic sponsors run the majority of device trials. Academic institutions frequently lack the centralized compliance systems and administrative resources of commercial sponsors, leading to higher rates of reporting delays.
The "Negative Result" Bias: Investigators and sponsors are often less motivated to compile and submit data for trials that fail to meet their primary efficacy endpoints.
FDAAA 801 Scope Nuances: Not all registered device trials are "applicable clinical trials" under FDAAA 801. Feasibility trials, early pilot studies, and trials conducted entirely outside the United States by foreign sponsors are often exempt from mandatory results submission, even if sponsors register them voluntarily for publication purposes.

The Consequences of Non-Compliance

Failing to submit required clinical trial results carries significant risks for device sponsors:

Civil Monetary Penalties: The FDA has the authority to impose civil penalties of up to $10,000 per day (adjusted annually for inflation, currently over $14,000 per day) for failure to submit required results.
Public Non-Compliance Notices: The FDA issues public Notices of Noncompliance to sponsors. These notices are posted on the ClinicalTrials.gov registry page for the study and are listed on the FDA's public compliance directory, creating significant reputational damage.
Withholding of Federal Funding: For academic institutions, non-compliance can lead to the National Institutes of Health (NIH) or other Federal agencies withholding future research grants.

7. The Strategic Value of Registry Data for B2B MedTech Decision-Makers

B2B MedTech companies must view ClinicalTrials.gov as a source of strategic insight, not just a regulatory chore. Because the database contains detailed protocols, study locations, and principal investigator names, clinical teams can use it for competitive intelligence and benchmarking.

Competitor Benchmarking and Pipeline Tracking

By scanning active registrations, sponsors can track exactly which competitors are running feasibility or pivotal trials, their target enrollment sizes, and their expected completion dates. For example, if a competitor registers a new pivotal trial for a cardiovascular catheter, their market-entry timeline can be estimated based on the average enrollment rate for similar trials in that specialty.

Investigator and Site Selection

The registry provides a complete directory of active clinical trial sites and principal investigators (PIs). When planning a trial, search the database to identify which sites are already running similar device trials. This helps locate high-performing sites with established patient access and experienced coordinators, reducing the risk of enrollment delays.

Regulatory and Design Precedents

When drafting a protocol for a pre-submission package to the FDA or an investigational device exemption (IDE) application, reviewing past registered trials of similar devices is invaluable. Sponsors can examine the primary endpoints, inclusion/exclusion criteria, and control arms used in successful pivotal trials, creating a regulatory precedent that simplifies FDA negotiations.

FAQs

Do all medical device clinical trials have to be registered on ClinicalTrials.gov?

No. Registration is legally required for "applicable device clinical trials" under FDAAA 801, which generally include trials of devices subject to FDA clearance or approval that evaluate safety or effectiveness in human subjects, other than small feasibility studies. However, many sponsors choose to register non-applicable trials (such as early feasibility trials or international studies) voluntarily to meet the publication requirements of major medical journals (ICMJE guidelines) and to support global commercialization.

How is the device trial count on ClinicalTrials.gov different from the FDA IDE database?

The FDA Investigational Device Exemption (IDE) database tracks trials approved by the FDA to test investigational devices in the United States. The ClinicalTrials.gov registry is much broader, containing international trials that do not require an FDA IDE, observational registries, post-market investigations, and academic research studies that are not intended to support an FDA submission.

What counts as an applicable device clinical trial under FDAAA 801?

An applicable device clinical trial is defined as a clinical trial that:

Is a prospective clinical study of health outcomes comparing an intervention with a device subject to FDA regulation against a control in human subjects, and
The study is studying a device other than a small feasibility study, and
The study has at least one clinical trial site in the United States, or the device is manufactured in the US and exported for clinical study.

Why do most device trials show phase NA instead of Phase 1 to Phase 3?

Because the traditional phase-based pathway (Phase 1–3) was designed for the biological and chemical testing of pharmaceuticals. Medical devices rely on physical, mechanical, or software interactions. Their safety and performance are evaluated using feasibility, pivotal, and post-market study designs rather than pharmaceutical phase progressions.

How often is the device trial count in this article likely to change?

Weekly. ClinicalTrials.gov is updated continually as sponsors register new studies, update recruitment statuses, and submit summary results. While the macro trends (such as the dominance of academic sponsors and the prevalence of Phase NA studies) remain highly stable, the absolute counts of registered studies increase by several hundred records each week.

Sources

ClinicalTrials.gov Trends and Charts on Registered Studies, U.S. National Library of Medicine / NIH. Available at: https://clinicaltrials.gov/about-site/trends-charts
ClinicalTrials.gov primary database extract, U.S. National Library of Medicine / NIH. Available via download portal: https://clinicaltrials.gov/data-download
FDAAA 801 and 42 CFR Part 11 (Clinical Trials Registration and Results Submission), U.S. Food and Drug Administration / National Archives. Available at: https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-11
Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000-2020, Journal of Medical Internet Research / PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9540299